Zobrazeno 1 - 10
of 114
pro vyhledávání: '"E, Orringer"'
Autor:
S. M. Grundy, N. J. Stone, A. L. Bailey, С. Beam, K. K. Birtcher, R. Blumenthal, L. T. Braun, S. de Ferranti, J. Faiella-Tommasino, D. E. Forman, R. Goldberg, P. A. Heidenreich, M. A. Hlatky, D. W. Jones, D. Lloyd-Jones, N. Lopez-Pajares, C. E. Ndumele, C. E. Orringer, C. A. Peralta, J. J Saseen, S. C. Smith, Jr. L. Sperling, S. S. Virani, J. Yeboah
Publikováno v:
Атеросклероз, Vol 15, Iss 4, Pp 5-32 (2019)
Externí odkaz:
https://doaj.org/article/9e278abefa554fd79d595c2766a25ac9
Autor:
Carl E. Orringer, Lale Tokgozoglu, Kevin C. Maki, Kausik K. Ray, Joseph J. Saseen, Alberico L. Catapano
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 21 (2020)
Despite consensus that excessive circulating concentrations of apoB‐lipoproteins is a key driver for the atherosclerotic process and that treatments that low‐density lipoprotein cholesterol lowering by up‐regulation of low‐density lipoprotein
Externí odkaz:
https://doaj.org/article/e0fa4fd9f8914ff2bb9030c588345bf2
Autor:
Carl E Orringer
Publikováno v:
European Heart Journal. 44:1461-1463
Autor:
Donald M. Lloyd-Jones, Pamela B. Morris, Christie M. Ballantyne, Kim K. Birtcher, Ashleigh M. Covington, Sondra M. DePalma, Margo B. Minissian, Carl E. Orringer, Sidney C. Smith, Ashley Arana Waring, John T. Wilkins
Publikováno v:
Journal of the American College of Cardiology. 80:1366-1418
Autor:
Jelani K. Grant, Michael Dangl, Margaret Koester, Mickias Tegegn, Leonardo Knijnik, Harjit Singh, Carl E. Orringer
Publikováno v:
Journal of Clinical Lipidology. 16:608-616
Non-Hispanic (NH) Black participants have been under-represented in studies of cardiovascular disease.We sought to determine the trends of reporting and representation of NH Black subjects in randomized controlled trials (RCTs) of lipid-lowering ther
Publikováno v:
Current Atherosclerosis Reports. 24:839-847
Autor:
Salim S, Virani, Marlys L, Koschinsky, Lisa, Maher, Anurag, Mehta, Carl E, Orringer, Raul D, Santos, Michael D, Shapiro, Joseph J, Saseen
Publikováno v:
Progress in Cardiovascular Diseases. 73:32-40
Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clin
Autor:
Neil J. Stone, Sidney C. Smith, Carl E. Orringer, Nancy A. Rigotti, Ann Marie Navar, Sadiya S. Khan, Daniel W. Jones, Ronald Goldberg, Samia Mora, Michael Blaha, Michael J. Pencina, Scott M. Grundy
Publikováno v:
Journal of the American College of Cardiology. 79:819-836
Publikováno v:
Journal of Clinical Lipidology. 15:782-788
For primary prevention, statin therapy reduces the incidence of atherosclerotic cardiovascular disease (ASCVD) events in adults with intermediate or high estimated 10-year risk using traditional population-based risk calculators. While a variety of r
Autor:
Paul A. Heidenreich, Donald M. Lloyd-Jones, Salim S. Virani, Carl E. Orringer, Lynne T. Braun, Scott M. Grundy, Joseph J. Saseen, Laurence S. Sperling, Roger S. Blumenthal, Neil J. Stone, Sidney C. Smith
Publikováno v:
Mayo Clinic Proceedings. 96:2660-2670
Review of the US and European literature indicates that most patients at high risk for atherosclerotic cardiovascular disease (ASCVD are not treated with high-intensity statins, despite strong clinical-trial evidence of maximal statin benefit. High-i